Starpharma Holdings Limited stock analysis
Starpharma Holdings Limited (PQ6) Stock Price & Analysis
PQ6 Stock Chart & Stats
- Day’s Range
- EUR 0.25 - EUR 0.25
- 52-Week Range
- EUR 0.16 - EUR 0.52
- Previous Close
- EUR 0.25
- Volume
- N/A
- Average Volume (3M)
- 343
- Market Cap
- EUR 126.06M
- Enterprise Value
- EUR 284.34M
- Total Cash (Recent Filing)
- EUR 11.02M
- Total Debt (Recent Filing)
- EUR 707.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.39
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Dendrimer Platform
Starpharma’s dendrimer platform supports multiple human-health applications, including pharmaceuticals, topical products and licensed formulations. This provides a reusable technology base that can support several commercial opportunities and diversify development efforts over the medium term.
Debt Reduction
The sharp reduction in debt materially lowers leverage and associated financial risk, giving Starpharma a more conservative capital structure. Lower obligations can preserve cash for research, product development and commercialisation while reducing pressure from interest and refinancing requirements.
Improved Cash Burn
Although cash flow remains negative, the marked improvement in 2026 indicates progress in controlling cash consumption. A lower burn rate can extend the company’s funding runway and provide greater flexibility to pursue its dendrimer pipeline while management works toward profitability.
Bears Say
Persistent Operating Losses
Continued operating and net losses show that Starpharma has not yet converted its technology and products into a profitable operating model. Ongoing losses can constrain reinvestment, increase reliance on external funding and delay the point at which growth translates into durable shareholder returns.
Negative Free Cash Flow
Persistent negative operating and free cash flow means the business continues to consume cash rather than finance operations internally. Unless profitability improves, recurring outflows may require additional funding and could limit the pace of research, development and commercial expansion.
Eroding Equity Base
The substantial decline in equity reflects the cumulative effect of losses and cash burn, leaving Starpharma with a smaller financial resource base than earlier years. This reduces balance-sheet flexibility and makes future investment or funding decisions more consequential if losses persist.
Starpharma Holdings Limited News
PQ6 FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
What is Starpharma Holdings Limited’s market cap?
When is Starpharma Holdings Limited’s upcoming earnings report date?
How were Starpharma Holdings Limited’s earnings last quarter?
Is Starpharma Holdings Limited overvalued?
Does Starpharma Holdings Limited pay dividends?
What is Starpharma Holdings Limited’s EPS estimate?
How many shares outstanding does Starpharma Holdings Limited have?
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Starpharma Holdings Limited Stock Smart Score
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cheryl Maley
- Employees
- 50
- Website
- starpharma.com
- Address
- Suite 3.02, Richmond, VIC, 3121, AU
Starpharma Holdings Limited (PQ6) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 5 | 16 |
| Technical Analysis | 1 | 5 | 4 |
| Moving Averages | 0 | 0 | 12 |








